Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Antonio Salar Silvestre"'
Autor:
Jorge Gomez, Guillermo Rodríguez, Christina Quero Blanco, Natalia Palazón-Carrión, Fatima de la Cruz-Vicente, Delvys Rodriguez-Abreu, Antonio Salar Silvestre, Fernando González, Pablo Espejo García, Antonio Rueda Dominguez, Concepción Nicolás, Eduardo Ríos Herranz, Luis Merino, Josep Guma, M. Guirado, Esteban Nogales Fernández, Mariano Provencio-Pulla, José Gómez-Codina, Natividad Martínez-Banaclocha, Alejandro Martín
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
8019 Background: Lenalidomide is an immunomodulatory drug that could reverse rituximab refractoriness in lymphoma patients (pts). We conducted an open label multicenter phase 2 trial testing the efficacy and toxicity of a combination of lenalidomide
Autor:
Matthias Schwenkglenks, Ruth Pettengell, Corinne Haioun, Francesca Gaia Rossi, Pieternella J. Lugtenburg, Ulrich Duehrsen, B. Pujol, Antonio Salar Silvestre, Tracey Wheeler, Gregor Verhoef
Publikováno v:
Hematology. 18:26-29
IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was
Autor:
Francesca Gaia Rossi, Antonio Salar Silvestre, Lucien Noens, Zsolt Szabo, Ulrich Jaeger, Wanda Krall, Pieternella J. Lugtenburg, Kate Bendall
Publikováno v:
Clinical lymphoma, myelomaleukemia. 12(5)
Improving the management of elderly patients with lymphoma is of increasing relevance. One thousand one hundred thirteen patients with diffuse large B-cell lymphoma (DLBCL) received rituximab (R)-CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubic
Autor:
Ruth, Pettengell, Hans E, Johnsen, Hans E, Johnson, Pieternella J, Lugtenburg, Antonio Salar, Silvestre, Ulrich, Dührsen, Francesca G, Rossi, Matthias, Schwenkglenks, Kate, Bendall, Zsolt, Szabo, Ulrich, Jaeger
Publikováno v:
Pettengell, R, Johnsen, H E, Lugtenburg, P J, Silvestre, A S, Dührsen, U, Rossi, F G, Schwenkglenks, M, Bendall, K, Szabo, Z & Jaeger, U 2012, ' Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma ', Supportive Care in Cancer, vol. 20, no. 3, pp. 647-52 . https://doi.org/10.1007/s00520-011-1306-6
Supportive Care in Cancer
Supportive Care in Cancer
Purpose\ud \ud This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations.\ud Methods\ud \ud Adults with diffuse large B-cell lymphoma (DLBCL) schedule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::988c7ca4081ba674c0c63ef051bd2989
https://pure.au.dk/portal/da/publications/impact-of-febrile-neutropenia-on-rchop-chemotherapy-delivery-and-hospitalizations-among-patients-with-diffuse-large-bcell-lymphoma(c36e5c35-65bd-49c6-86a0-8b042df48fd9).html
https://pure.au.dk/portal/da/publications/impact-of-febrile-neutropenia-on-rchop-chemotherapy-delivery-and-hospitalizations-among-patients-with-diffuse-large-bcell-lymphoma(c36e5c35-65bd-49c6-86a0-8b042df48fd9).html
Autor:
Pilar Giraldo Castellano, María José Terol Castera, María José Sánchez, Jose Antonio Marquez Navarro, Antonio Salar Silvestre, Carlos Montalbán Sanz, María Dolores Caballero Barrigón, Antonio Gutiérrez García, Juan-Manuel Sancho Cia, Blanca Gonzalez, Miguel Ángel Canales Albendea, Francisco Javier Capote Huelva, Soledad Durán Nieto, Francisco Javier Peñalver Párraga
Publikováno v:
Web of Science
Objectives: To evaluate the efficacy and toxicity of a response-adapted therapy with rituximab/bendamustine/mitoxantrone/dexamethasone (RBMD), followed by rituximab (R) maintenance therapy in patients with relapsed or refractory follicular lymphoma (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::092287eb29227e62c22a0a6f30a70cd2
https://publons.com/wos-op/publon/53891760/
https://publons.com/wos-op/publon/53891760/